Pfiz­er, Mer­ck KGaA run in­to a se­vere set­back as PD-L1 drug Baven­cio fails in PhI­II gas­tric can­cer study

Pfiz­er $PFE and its part­ner Mer­ck KGaA have run in­to a dead end in their race to ex­pand the mar­ket for their PD-L1 check­point Baven­cio (avelum­ab). Re­searchers to­day con­ced­ed that the check­point — one of 5 now scram­bling to ex­pand their mar­ket turf in the mega-block­buster glob­al on­col­o­gy busi­ness — failed to sig­nif­i­cant­ly im­prove over­all sur­vival for ad­vanced gas­tric can­cer pa­tients com­pared to best stan­dard of care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER